(HLUN-B) H Lundbeck - Ratings and Ratios
Pharmaceuticals, Neurological, Psychiatric, Disorders, Treatments
HLUN-B EPS (Earnings per Share)
HLUN-B Revenue
Description: HLUN-B H Lundbeck
H. Lundbeck A/S is a pharmaceutical company specializing in the treatment of psychiatric and neurological disorders. The companys product portfolio includes a range of medications for conditions such as schizophrenia, depression, bipolar disorder, epilepsy, Parkinsons disease, and migraine prevention.
The companys key products include Abilify Maintena/Abilify Asimtufii, Brintellix/Trintellix, Rexulti/Rxulti, Vyepti, and Cipralex/Lexapro, among others. These products have a significant presence in Europe and the United States, and are used to treat a variety of serious health conditions.
Lundbecks pipeline includes several promising candidates in various stages of clinical trials, such as Eptinezumab for migraine prevention and cluster headache, Lu AG09222 for migraine prevention, and Lu AF28996 for Parkinsons disease. The companys research focus is on developing innovative treatments for neurological and psychiatric disorders.
From a financial perspective, H. Lundbeck A/S has a market capitalization of approximately 35 billion DKK, with a price-to-earnings ratio of 10.70 and a forward P/E of 9.08. The companys return on equity is 13.61%, indicating a relatively strong profitability. Additional key performance indicators (KPIs) to consider include revenue growth, R&D expenses as a percentage of revenue, and debt-to-equity ratio.
To further evaluate Lundbecks performance, we can examine its revenue diversification across different regions and products, as well as its gross margin and operating margin. The companys ability to successfully commercialize its products and advance its pipeline will be crucial to its long-term success. Key metrics to monitor include the progress of its clinical trials, regulatory approvals, and sales growth.
HLUN-B Stock Overview
| Market Cap in USD | 5,885m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception |
HLUN-B Stock Ratings
| Growth Rating | 2.13% |
| Fundamental | 69.1% |
| Dividend Rating | 57.7% |
| Return 12m vs S&P 500 | -25.5% |
| Analyst Rating | - |
HLUN-B Dividends
| Dividend Yield 12m | 2.36% |
| Yield on Cost 5y | 3.12% |
| Annual Growth 5y | 9.86% |
| Payout Consistency | 100.0% |
| Payout Ratio | 17.2% |
HLUN-B Growth Ratios
| Growth Correlation 3m | 35% |
| Growth Correlation 12m | -76% |
| Growth Correlation 5y | 67.2% |
| CAGR 5y | 9.84% |
| CAGR/Max DD 5y | 0.23 |
| CAGR/Mean DD 5y | 0.64 |
| Sharpe Ratio 12m | -0.50 |
| Alpha | -26.46 |
| Beta | 0.769 |
| Volatility | 27.37% |
| Current Volume | 230.1k |
| Average Volume 20d | 358.9k |
| Stop Loss | 40 (-3.1%) |
| Signal | 0.27 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (3.48b TTM) > 0 and > 6% of Revenue (6% = 1.41b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -5.06pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 19.07% (prev 34.38%; Δ -15.31pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 3.41b <= Net Income 3.48b (YES >=105%, WARN >=100%) |
| Net Debt (10.54b) to EBITDA (3.44b) ratio: 3.06 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.59 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (991.9m) change vs 12m ago 0.48% (target <= -2.0% for YES) |
| Gross Margin 81.55% (prev 78.43%; Δ 3.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 51.76% (prev 52.95%; Δ -1.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 30.44 (EBITDA TTM 3.44b / Interest Expense TTM 113.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.45
| (A) 0.09 = (Total Current Assets 12.02b - Total Current Liabilities 7.54b) / Total Assets 51.80b |
| (B) 0.45 = Retained Earnings (Balance) 23.51b / Total Assets 51.80b |
| (C) 0.08 = EBIT TTM 3.44b / Avg Total Assets 45.45b |
| (D) 0.85 = Book Value of Equity 23.51b / Total Liabilities 27.61b |
| Total Rating: 3.45 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 69.10
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 5.14% = 2.57 |
| 3. FCF Margin 12.12% = 3.03 |
| 4. Debt/Equity 0.86 = 2.15 |
| 5. Debt/Ebitda 6.02 = -2.50 |
| 6. ROIC - WACC 2.14% = 2.68 |
| 7. RoE 14.28% = 1.19 |
| 8. Rev. Trend 94.56% = 4.73 |
| 9. Rev. CAGR 9.28% = 1.16 |
| 10. EPS Trend 43.74% = 1.09 |
| 11. EPS CAGR 27.44% = 2.50 |
What is the price of HLUN-B shares?
Over the past week, the price has changed by +2.89%, over one month by +18.36%, over three months by +3.67% and over the past year by -10.40%.
Is H Lundbeck a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HLUN-B is around 39.56 DKK . This means that HLUN-B is currently overvalued and has a potential downside of -4.12%.
Is HLUN-B a buy, sell or hold?
What are the forecasts/targets for the HLUN-B price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 47.8 | 15.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 43.1 | 4.4% |
HLUN-B Fundamental Data Overview
Market Cap DKK = 37.34b (37.34b DKK * 1.0 DKK.DKK)
CCE Cash And Equivalents = 2.65b DKK (Cash only, last quarter)
P/E Trailing = 11.0909
P/E Forward = 9.6154
P/S = 1.5875
P/B = 1.601
P/EG = 8.0471
Beta = 0.301
Revenue TTM = 23.52b DKK
EBIT TTM = 3.44b DKK
EBITDA TTM = 3.44b DKK
Long Term Debt = 13.19b DKK (from longTermDebt, last quarter)
Short Term Debt = 7.54b DKK (from totalCurrentLiabilities, last quarter)
Debt = 20.72b DKK (Calculated: Short Term 7.54b + Long Term 13.19b)
Net Debt = 10.54b DKK (from netDebt column, last quarter)
Enterprise Value = 55.42b DKK (37.34b + Debt 20.72b - CCE 2.65b)
Interest Coverage Ratio = 30.44 (Ebit TTM 3.44b / Interest Expense TTM 113.0m)
FCF Yield = 5.14% (FCF TTM 2.85b / Enterprise Value 55.42b)
FCF Margin = 12.12% (FCF TTM 2.85b / Revenue TTM 23.52b)
Net Margin = 14.82% (Net Income TTM 3.48b / Revenue TTM 23.52b)
Gross Margin = 81.55% ((Revenue TTM 23.52b - Cost of Revenue TTM 4.34b) / Revenue TTM)
Tobins Q-Ratio = 2.36 (Enterprise Value 55.42b / Book Value Of Equity 23.51b)
Interest Expense / Debt = 0.55% (Interest Expense 113.0m / Debt 20.72b)
Taxrate = 15.49% (576.0m / 3.72b)
NOPAT = 2.91b (EBIT 3.44b * (1 - 15.49%))
Current Ratio = 1.59 (Total Current Assets 12.02b / Total Current Liabilities 7.54b)
Debt / Equity = 0.86 (Debt 20.72b / last Quarter total Stockholder Equity 24.19b)
Debt / EBITDA = 6.02 (Net Debt 10.54b / EBITDA 3.44b)
Debt / FCF = 7.27 (Debt 20.72b / FCF TTM 2.85b)
Total Stockholder Equity = 24.40b (last 4 quarters mean)
RoA = 6.73% (Net Income 3.48b, Total Assets 51.80b )
RoE = 14.28% (Net Income TTM 3.48b / Total Stockholder Equity 24.40b)
RoCE = 9.15% (Ebit 3.44b / (Equity 24.40b + L.T.Debt 13.19b))
RoIC = 8.00% (NOPAT 2.91b / Invested Capital 36.34b)
WACC = 5.86% (E(37.34b)/V(58.06b) * Re(8.85%)) + (D(20.72b)/V(58.06b) * Rd(0.55%) * (1-Tc(0.15)))
Shares Correlation 5-Years: -97.50 | Cagr: -0.06%
Discount Rate = 8.85% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 78.87% ; FCFE base≈3.36b ; Y1≈4.15b ; Y5≈7.08b
Fair Price DCF = 130.5 (DCF Value 103.38b / Shares Outstanding 792.4m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 94.56 | Revenue CAGR: 9.28%
Rev Growth-of-Growth: 5.04
EPS Correlation: 43.74 | EPS CAGR: 27.44%
EPS Growth-of-Growth: 62.52